Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo oral solution Clear all
Terminated Phase 2 Interventional Results available

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

NCT01680172
View directory record Official record
Conditions
Cancer, Depression, Anxiety
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Yuma, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

NCT00777595
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo, Moxifloxacin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

NCT03201419
View directory record Official record
Conditions
Nocturia
Interventions
FE 201836, Desmopressin, Placebo oral solution, Placebo ODT
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Pioglitazone, Placebo Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01309932
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 23, 2026, 2:28 PM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

NCT04412252
View directory record Official record
Conditions
COVID-19
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Hartford, Connecticut • Iowa City, Iowa • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 23, 2026, 2:28 PM EDT
Enrolling by invitation Phase 1 Interventional

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

NCT05301361
View directory record Official record
Conditions
Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Oral Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 24 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study Of Increasing Oral Doses Of PF-04634817

NCT01098877
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817 Placebo, PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
View directory record Official record
Conditions
Cocaine Dependency
Interventions
CPP-115, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 23, 2026, 2:28 PM EDT
Not listed Phase 3 Interventional

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

NCT04762758
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease
Interventions
(RS)-baclofen, naltrexone hydrochloride and D-sorbitol, Placebo
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
16 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Los Angeles, California • Sacramento, California • New Britain, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

NCT01442532
View directory record Official record
Conditions
Healthy Male Volunteer
Interventions
JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 23, 2026, 2:28 PM EDT
Recruiting Phase 1 Interventional

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

NCT06393101
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
BRC-002, BRC-002 Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06474 in Healthy Young Men

NCT05003687
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

NCT00453999
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose (BMS-813160) Study

NCT01049165
View directory record Official record
Conditions
Accelerated Intimal Hyperplasia
Interventions
BMS-813160, [14C] BMS-813160, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Not applicable Interventional Results available

The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess

NCT03005522
View directory record Official record
Conditions
Dental Research, Pharmaceutical Preparations, Dental
Interventions
oral dexamethasone, Placebo Oral Capsule
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

NCT03715153
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 6 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Terminated Phase 3 Interventional Results available

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

NCT04815083
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer
Interventions
Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System, Placebo
Drug · Device
Lead sponsor
SBI ALApharma Canada, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Stamford, Connecticut • Clearwater, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 23, 2026, 2:28 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Comparison of IV Versus PO Acetaminophen Postoperatively for Opioid Consumption After Cesarean Section

NCT04290208
View directory record Official record
Conditions
Postoperative Pain, Cesarean Section, Acetaminophen
Interventions
Acetaminophen, Placebos
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

NCT01914796
View directory record Official record
Conditions
Healthy
Interventions
PF-06412562
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 23, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

Ketamine in Chronic Kid's (KiCK) Pain

NCT01755169
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 23, 2026, 2:28 PM EDT